Polymerase Chain Reaction Market

Polymerase Chain Reaction Market Outlook

Demand for polymerase chain reaction tests is anticipated to reach US$ 3.6 Bn by 2021-end, further expanding to US$ 12 Bn at the conclusion of the 2021-2031 assessment period, according to a recent report published by Fact.MR. The market is poised to expand 3x, with PCR reagents set to capture 60% of total revenue.

Market Size (2021)	US$ 3.6 Bn
Projected Market Value (2031)	US$ 12 Bn
Value CAGR (2021-2031)	10%

Revenue from Polymerase Chain Reaction Industry from 2016 to 2020 Compared to Demand Outlook for 2021 to 2031

Over the past half decade, various factors drove the growth of the global Polymerase Chain Reaction (PCR) market, such as mounting prevalence of chronic and infectious diseases  and swelling application of PCR. This has ultimately escalated the demand for Polymerase Chain Reaction (PCR) to grow at a CAGR of 8.4% during the historic period 2016-2020.

The dreadful impact of SARS-CoV-2, surged the need for reliable and rapid detection systems, such as qPCR. It is the gold standard for detecting the novel coronavirus, owing to its higher specificity and sensitivity than other tests. 

Further, growing adoption of technological advancements and hasty investments in pharmaceutical and healthcare industry pushed the market towards a positive trajectory. In the forthcoming years, the global PCR market is projected to Expand at an anticipated CAGR of 10% and is set to surpass US$ 12 Bn by 2026.

What are the Factors Driving the Demand for Polymerase Chain Reaction?

The growth PCR technologies market is primarily driven by the rising incidences of target diseases and genetic disorders; continuous technological advancements in PCR technologies, the development of miniaturized portable instruments, and incorporation of robotics; increasing investments, funds, and grants for research activities; increasing use of biomarker profiling for disease diagnostics; and the successful completion of the Human Genome Project.

The demand for genomic analysis techniques has grown steadily during the last decade on the back of their increasing use (microbial identification and detection of genetic mutations) in the diagnosis of major infectious diseases (such as tuberculosis, HIV, malaria, hepatitis, and Staph-related diseases) and genetic disorders (such as cancer and fragile X syndrome).

Additionally, with the proven efficacy of PCR analysis in the diagnosis and estimation of disease-causing microbes, the market will observe clinical diagnostic tests (including qPCR and dPCR analysis) and support market growth. COVID-19 was declared a pandemic by the World Health Organization (WHO) in March, 2020. The necessity of a highly sensitive molecular diagnosis is anticipated to considerably reduce false negatives reverse transcription PCR (RT-PCR) results, raised as a major clinical need for a robust diagnostic tool for the detection of COVID-19 owing to the global pandemic. 

Frequent Pandemic & Epidemic Outbreaks to Fuel Polymerase Chain Reaction Demand?

Emergent markets are anticipated to offer substantial growth opportunities, led by the intensifying incidence of infectious and chronic diseases, along with soaring R&D initiatives to develop innovative genomic techniques such as PCR. Growth will be reinforced by the expansion of healthcare infrastructure, upsurge in healthcare expenditure, and reducing procedural costs for qPCR-based and dPCR-based disease diagnosis in emerging countries.

Evolving countries are beholding rapid modernization in healthcare facilities and the expansion of healthcare infrastructure. This factor is contributing to the growing demand for clinical diagnostic procedures among diagnostic laboratories, which is resulting in the augmented sales of clinical PCR products.

Consequently, a surge in pharmaceutical R&D budgets by governments and private players is predicted to stimulate growth prospects of the global polymerase chain reaction (PCR) market in the future. Also, increase in prevalence of chronic and infectious diseases is projected to push the demand for PCR solutions during the forecast period (2020-2026).

The development of RT-qPCR kits that can detect SARS-CoV-2, coupled with their wide acceptance globally, is a major factor likely to fuel the market. For instance, RT-PCR diagnostic panel CDC 2019-Novel Coronavirus was approved in June 2020 by the FDA for diagnosis of the novel coronavirus.

Region-wise Analysis

Why is Asia Witnessing Positive Growth in the PCR Industry?

Asia accounts for nearly 18.6% share and is anticipated to experience healthy growth during the forecast period. Growing awareness among physicians and healthcare professionals about the benefits of gene-based disease diagnosis and treatment. Moreover, growing public-private support to develop novel PCR technologies have accounted for a particularly high growth rate in this region.

This is primarily due to improvements in healthcare infrastructure, a rise in public and private investment in life science research, and technological advancements in the healthcare industry in developing economies.

Significant expansion of market players through licensing and distribution agreements with local players is also anticipated to fuel the PCR market growth. A prolific CAGR of 9.5% is projected for Asia for the timeframe.

What’s Fuelling Demand of Polymerase Chain Reaction in the North America?

North America is foreseen to remain the kingpin of the global PCR market, accounting for nearly 46.2% share. Growth is attributed to healthcare infrastructure modernization, increasing penetration of cutting-edge diagnostic technologies (including PCR technologies) for research and clinical applications.

This growth is attributed to adoption of novel biotechnologies, augmented awareness about PCR products, significant fund allocation for research in national budgets, early availability of advanced technologies, and a rise in R&D activities in the region. The region is poised to expand at a growth rate of 7.5% annually.

Category-wise insights

Which End Use Industry Will Emerge as Key Market Contributor?

Pharmaceutical and biotechnology Industries are poised to capture a major chunk of the global market for polymerase chain reaction. Snowballing test volumes and laboratory automation are projected to drive demand for PCR services in the pharmaceutical and biotechnology industries. Gigantic strides made in the domain of pharmacogenomics, and rising trend of self-diagnosis of ailments will further advance the PCR market growth.

Burgeoning investments in R&D of genetic engineering and competition in the discovery of new drugs for diseases such as HIV-AIDS and cancer will also boost growth prospects. Adoption of PCR in pharmaceutical and biotechnology industries is anticipated to grow impressively at a CAGR of 8.6% in the forecast period.

Why are PCR Reagents Highly Sought After?

PCR reagents are anticipated to capture 3/5th of the total market share during the forecast period. Continuous increase in the number of diagnostic tests and launch of new reagents specific to the test type are set to augment demand for reagents used in polymerase chain reaction.

Additionally, significant demand for testing supplies for the SARS-CoV-2 pandemic and the amplified availability of technologically advanced diagnostic equipment in countries with unmet clinical needs will foster PCR market sales. Along with this, the launch of new products is likely to contribute to the growth of the segment. For instance, in March 2021, PCR Biosystems announced the launch of its IsoFast Bst Polymerase reagents that support sensitive, robust, and rapid amplification of RNA and DNA, which enables faster testing procedures.

Competitive Landscape

Prominent players are embracing innovative approaches such as ground-breaking marketing tactics, technological advancements, mergers, and acquisitions to expand their footprint.

• In October 2021, US based Thermo Fisher Scientific, provider of scientific instrumentation, reagents and consumables, introduced the Applied Biosystem QuantStudio Absolute Q-Digital PCR System, the first fully integrated digital PCR (dPCR) system designed to provide highly accurate and consistent results in genetic analysis and research within 90 minutes.
• In March 2021, Agilent Technologies Inc., announced the launch of a real-time reverse transcription (qRT) PCR-based diagnostic kit for the detection of SARS-CoV-2 RNA. The CE-IVD mark is in accordance with the European Union In-Vitro Diagnostic Directive 98/79/EC and is available for immediate distribution.

Report Scope

Forecast Period	2021-2031
Historical Data Available for	2016-2020
Market Analysis	US$ Mn for Value & Units for Volume
Key Regions Covered	North America Latin America Europe East Asia South Asia Oceania Middle East & Africa
Key Countries Covered	U.S. Canada Germany U.K. France Spain Italy Russia China Japan India Australia New Zealand Brazil Mexico GCC    South Africa
Key Companies Profiled	Bio-Rad Laboratories Inc. Qiagen N.V Roche Diagnostics Becton Dickinson & Company (BD) Abbott Laboratories Siemens Healthineers BioMerieux S.A Danaher Corporation Thermo Fisher Scientific Inc. Agilent Technologies

Key Segments Covered

• Product

  • PCR Instruments
  • Standard PCR Systems
  • RT PCR Systems
  • Digital PCR Systems
  • PCR Reagents
  • PCR Consumables

• End User

  • PCR for Pharmaceutical & Biotechnology Industries
  • PCR for Clinical Diagnostics Labs and Hospitals
  • PCR for Academic and Research Organizations
  • PCR for Other End Users